Although it is known that trastuzumab causes cardiotoxicity, its extent and reversibility are still in question. Earlier studies have not evaluated consecutive patients with reproducible nuclear ventriculography.We sought to evaluate the baseline characteristics which predispose patients to increased risk of trastuzumab cardiotoxicity and to determine the natural history of the cardiotoxicity.Left ventricular ejection fraction (LVEF) was measured in 76 women aged 36-73 years who had been treated with trastuzumab at the University of Maryland Greenebaum Cancer Center. LVEF was determined at baseline and then 3, 6, 9, and 12 months after treatment initiation. Cardiotoxicity was defined as ≥ 16

作者：Kaitlin B, Baron；Jennifer R, Brown；Brian L, Heiss；Joanne, Marshall；Nancy, Tait；Katherine H R, Tkaczuk；Stephen S, Gottlieb

来源：Journal of cardiac failure 2014 年 20卷 8期